It is used for respiratory tract infections, exacerbation of chronic bronchitis, and acute sinusitis.
Each film-coated tablet contains 400 mg of moxifloxacin (as hydrochloride).
Contains 68 mg of lactose monohydrate per tablet.
Indicated for the treatment of the following bacterial infections caused by susceptible strains:
Respiratory tract infections
Exacerbation of chronic bronchitis
Community-acquired pneumonia, including cases caused by multi-drug resistant strains
Acute sinusitis
Uncomplicated skin and skin structure infections
Uncomplicated pelvic inflammatory disease (e.g., upper genital tract infections in women including salpingitis and endometritis)
Complicated skin and skin structure infections (including diabetic foot infections)
Complicated intra-abdominal infections, including polymicrobial infections such as abscesses
The recommended dose of Aveloxi is 400 mg once daily.
The film-coated tablet should be swallowed whole with sufficient liquid, independently of food intake.
The duration of treatment should be determined based on severity or clinical response. The following general recommendations exist for upper and lower respiratory tract infections:
Bronchitis: Exacerbation of chronic bronchitis, 5 days
Pneumonia: Community-acquired pneumonia, 10 days
Sinusitis: Acute sinusitis, 7 days
Uncomplicated skin and skin structure infections: 7 days
Uncomplicated pelvic inflammatory disease: 14 days
Complicated skin and skin structure infections:
Total duration of therapy after intravenous or oral treatment: 7–21 days
Complicated intra-abdominal infections:
Total duration of therapy after intravenous and oral treatment: 5–14 days
Store at a temperature not exceeding 30°C. Keep in the original packaging and container.
Keep out of reach of children.
Shelf life: tablets – 4 years.
